-
公开(公告)号：US20160168116A1
公开(公告)日：2016-06-16
申请号：US14969837
申请日：2015-12-15
申请人： MannKind Corporation
IPC分类号： C07D333/58 , C07D333/22 , C07D239/26 , C07D321/10 , C07C65/30 , C07C205/44 , C07D317/54 , C07D231/12 , C07D307/80 , C07D213/69 , C07D319/18 , C07D261/08 , C07D213/48 , C07C47/565 , C07D215/14 , C07D217/16 , C07D295/192 , C07C235/84 , C07C317/24 , C07D295/15 , C07D241/18 , C07C47/575
CPC分类号： C07C65/21 , A61K31/11 , A61K31/135 , A61K31/166 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C47/55 , C07C47/565 , C07C47/575 , C07C65/11 , C07C65/26 , C07C65/30 , C07C205/44 , C07C205/61 , C07C223/02 , C07C233/65 , C07C235/42 , C07C235/84 , C07C251/24 , C07C317/24 , C07C321/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/48 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D217/16 , C07D231/12 , C07D235/08 , C07D239/26 , C07D239/54 , C07D241/18 , C07D249/18 , C07D261/08 , C07D277/34 , C07D295/125 , C07D295/15 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/08 , C07D319/18 , C07D321/10 , C07D333/22 , C07D333/58 , C07D401/12 , C07D403/12 , C07D417/10 , Y02A50/389 , Y02A50/393
摘要： Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译： 在体外直接抑制IRE-1α活性的化合物，其前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病，并可用作单一药剂或联合疗法。
-
公开(公告)号：US20170152206A1
公开(公告)日：2017-06-01
申请号：US15356292
申请日：2016-11-18
申请人： MannKind Corporation
IPC分类号： C07C65/21 , C07C65/11 , C07C233/65 , C07C65/26
CPC分类号： C07C65/21 , A61K31/11 , A61K31/135 , A61K31/166 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C47/55 , C07C47/565 , C07C47/575 , C07C65/11 , C07C65/26 , C07C65/30 , C07C205/44 , C07C205/61 , C07C223/02 , C07C233/65 , C07C235/42 , C07C235/84 , C07C251/24 , C07C317/24 , C07C321/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/48 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D217/16 , C07D231/12 , C07D235/08 , C07D239/26 , C07D239/54 , C07D241/18 , C07D249/18 , C07D261/08 , C07D277/34 , C07D295/125 , C07D295/15 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/08 , C07D319/18 , C07D321/10 , C07D333/22 , C07D333/58 , C07D401/12 , C07D403/12 , C07D417/10 , Y02A50/389 , Y02A50/393
摘要： Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
-
公开(公告)号：US09546149B2
公开(公告)日：2017-01-17
申请号：US14969837
申请日：2015-12-15
申请人： MannKind Corporation
IPC分类号： C07D213/48 , C07C65/30 , A61K31/11 , C07D333/58 , C07C47/55 , C07C47/565 , C07C47/575 , C07D213/64 , C07D213/69 , C07D213/74 , C07D217/16 , C07D231/12 , C07D239/26 , C07D239/54 , C07D261/08 , C07D277/34 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/18 , C07D321/10 , C07D333/22 , C07D417/10 , A61K31/135 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C205/44 , C07D295/125 , C07C235/84 , C07C317/24 , C07D215/14 , C07D241/18 , C07D295/15
CPC分类号： C07C65/21 , A61K31/11 , A61K31/135 , A61K31/166 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C47/55 , C07C47/565 , C07C47/575 , C07C65/11 , C07C65/26 , C07C65/30 , C07C205/44 , C07C205/61 , C07C223/02 , C07C233/65 , C07C235/42 , C07C235/84 , C07C251/24 , C07C317/24 , C07C321/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/48 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D217/16 , C07D231/12 , C07D235/08 , C07D239/26 , C07D239/54 , C07D241/18 , C07D249/18 , C07D261/08 , C07D277/34 , C07D295/125 , C07D295/15 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/08 , C07D319/18 , C07D321/10 , C07D333/22 , C07D333/58 , C07D401/12 , C07D403/12 , C07D417/10 , Y02A50/389 , Y02A50/393
摘要： Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译： 在体外直接抑制IRE-1α活性的化合物，其前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病，并可用作单一药剂或联合疗法。
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
